STOCK TITAN

Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vir Biotechnology, Inc. director Timothy Coughlin reported compensation-related equity grants. He acquired two awards of 8,000 shares of common stock each at no cost, in the form of restricted stock units under the company’s Equity Incentive Plan. He also received two stock option grants covering 16,000 shares each at an exercise price of $8.51 per share, expiring in 2036. Portions of the RSUs and options begin vesting on June 9, 2027, with remaining amounts vesting over time or in full by the earlier of that date or the next annual meeting of stockholders. Following these grants, one reported common stock position shows 16,000 shares held directly.

Positive

  • None.

Negative

  • None.
Insider Coughlin Timothy
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,000 $0.00 --
Grant/Award Stock Option (Right to Buy) 16,000 $0.00 --
Grant/Award Common Stock 8,000 $0.00 --
Grant/Award Common Stock 8,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 16,000 shares (Direct, null); Common Stock — 8,000 shares (Direct, null)
Footnotes (1)
  1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter. The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter. The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
RSU grant size 1 8,000 shares Restricted stock unit award of common stock
RSU grant size 2 8,000 shares Second restricted stock unit award of common stock
Option grant size 1 16,000 shares Stock option grant, right to buy common stock
Option grant size 2 16,000 shares Second stock option grant, right to buy common stock
Option exercise price $8.51 per share Conversion or exercise price for stock options
Option expiration June 8, 2036 Expiration date of stock option grants
Common shares after grant 16,000 shares Total common stock held directly after one grant entry
Initial vesting date June 9, 2027 First vesting date for RSUs and options
restricted stock units (RSUs) financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Equity Incentive Plan financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
stock option financial
"1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of stockholders financial
"The RSUs will vest in full on the earlier of June 9, 2027, or the date of the Issuer's next annual meeting of stockholders."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Coughlin Timothy

(Last)(First)(Middle)
C/O VIR BIOTECHNOLOGY, INC.
1800 OWENS STREET, SUITE 900

(Street)
SAN FRANCISCO CALIFORNIA 94158

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/09/2026A(1)8,000(2)A$08,000D
Common Stock06/09/2026A(1)8,000(3)A$016,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.5106/09/2026A16,000 (4)06/08/2036Common Stock16,000$016,000D
Stock Option (Right to Buy)$8.5106/09/2026A16,000 (5)06/08/2036Common Stock16,000$016,000D
Explanation of Responses:
1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
2. 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter.
3. The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
4. 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter.
5. The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
Remarks:
/s/ Vanina de Verneuil, Attorney-In-Fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Vir Biotechnology (VIR) director Timothy Coughlin receive?

Timothy Coughlin received two restricted stock unit grants of 8,000 shares each and two stock option grants covering 16,000 shares each. All awards were granted at no cash cost as part of his director compensation.

What is the exercise price and expiration for Timothy Coughlin’s Vir (VIR) stock options?

Each stock option grant to Timothy Coughlin covers 16,000 shares at an exercise price of $8.51 per share. The options are scheduled to expire on June 8, 2036, if not exercised or otherwise terminated earlier.

How do Timothy Coughlin’s Vir (VIR) restricted stock units vest?

One RSU grant vests one-third on June 9, 2027, with the balance in two equal annual installments. Another RSU grant vests in full on the earlier of June 9, 2027, or Vir’s next annual meeting of stockholders.

How do Timothy Coughlin’s Vir (VIR) stock options vest over time?

One option grant vests one-third on June 9, 2027, with the remaining shares vesting in 24 equal monthly installments. Another option grant vests in full on the earlier of June 9, 2027, or Vir’s next annual meeting.

Did Timothy Coughlin buy or sell Vir (VIR) shares on the open market?

The filing reports compensation grants only, coded as acquisitions (A), not open-market purchases or sales. Restricted stock units and stock options were awarded under Vir Biotechnology’s Equity Incentive Plan at no cash purchase price.

How many Vir (VIR) common shares does Timothy Coughlin hold after these grants?

One reported common stock line item shows 16,000 shares held directly following the grant activity. Additional potential ownership comes from the newly awarded restricted stock units and stock options, which vest and become exercisable over time.